Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: A Danish Cohort Study

Laryngoscope

Volumn 112, Issue 11, 2002, Pages 2009-2014

  Johansen, Jørgen ^a   Eigtved, Annika ^a   Buchwald, Christian ^a   Theilgaard, Sune A ^a   Hansen, Hanne S ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Carcinoma of unknown primary; Head and neck cancer; Lymph node metastases; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ABDOMINAL CANCER; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARGE CELL CARCINOMA; LUNG CARCINOMA; LYMPH NODE METASTASIS; MALE; MOUTH CARCINOMA; NASOPHARYNX CARCINOMA; NECK DISSECTION; NECK METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; UNDIFFERENTIATED CARCINOMA;

EID: 0036843878     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200211000-00018     Document Type: Article

References (20)

1. Muir C. Cancer of unknown primary site. Cancer 1995;75(Suppl):353-356.
2. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours: results from a national survey by the Danish Society for Head Neck Oncology. Radiother Oncol 2000;55:121-129.
3. Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: Cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 2001;50:727-733.
4. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995;36:1747-1757.
5. Stokkel MP, ten Boek F-W, van Rijk PP. Preoperative assessment of cervical lymph nodes in head and neck cancer with fluorine-18 fluorodeoxyglucose using a dual-head coincidence camera: A pilot study. Eur J Nucl Med 1999;26:499-503.
6. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur JNucl Med 1998;25:1255-1260.
7. Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997;26:112-115.
8. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-1166.
9. AAssar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999;210:177-181.
10. Greven KM, Keyes JWJ, Williams DW, McGuirt WF, Joyce WT. Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer 1999;86:114-118.
11. Safa AA, Tran LM, Rege S, et al. The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am 1999;5:214-218.
12. Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography. Oral Oncol 1999;35:390-394.
13. Bohuslavizki KH, Klutmann S, Kroger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816-822.
14. Jungehülsing M, Scheidhauer K, Damm M, et al. 2 [F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000;123:294-301.
15. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880-885.
16. Overgaard J, Hansen HS, Grau C, et al. The DAHANCA 6 and 7 trial: A randomized multicenter study of 5 versus 6 fractions per week of conventional radiotherapy of squamous cell carcinoma (SCC) of the head and neck. Radiother Oncol 2000;56(Suppl 1):S4.
17. Wong WL, Saunders M. Role of PET FDG in the management of head and neck squamous cell cancer. Clin Oncol 1998;10:361-366.
18. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001;345:1877-1882.
19. Lee WY, Hsiao JR, Jin YT, Tsai ST. Epstein-Barr virus detection in neck metastases by in-situ hybridization in fine-needle aspiration cytologic studies: An aid for differentiating the primary site. Head Neck 2000;22:336-340.
20. Liu MY, Chang YL, Ma J, et al. Evaluation of multiple antibodies to Epstein-Barr virus as markers for detecting patients with nasopharyngeal carcinoma. J Med Virol 1997;52:262-269.